# BGS649 Monotherapy in Moderate to Severe Endometriosis Patients

> **NCT01190475** · PHASE2 · COMPLETED · sponsor: **Mereo BioPharma** · enrollment: 6 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** Active treatment with a high dose of BGS649
- **DRUG:** Active treatment with a low dose of BGS649
- **DRUG:** Placebo treatment to blind study

## Key facts

- **NCT ID:** NCT01190475
- **Lead sponsor:** Mereo BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2020-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01190475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01190475, "BGS649 Monotherapy in Moderate to Severe Endometriosis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01190475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*